Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
| Autor: | Jacob Teperman, Michael H. Pillinger, Aaron Z Reyes, Jean-Claude Tardif, Theresa Wampler Muskardin, Binita Shah, Kelly A Hu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) Adverse outcomes medicine.drug_class Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Anti-Inflammatory Agents Inflammation 030204 cardiovascular system & hematology Article Anti-inflammatory General Biochemistry Genetics and Molecular Biology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Rheumatology Health care medicine Humans Colchicine Immunology and Allergy Intensive care medicine 030203 arthritis & rheumatology Biological therapies SARS-CoV-2 business.industry COVID-19 Drug Treatment chemistry medicine.symptom business |
| Zdroj: | Annals of the Rheumatic Diseases Ann Rheum Dis |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2020-219174 |
| Popis: | The search for effective COVID-19 management strategies continues to evolve. Current understanding of SARS-CoV-2 mechanisms suggests a central role for exaggerated activation of the innate immune system as an important contributor to COVID-19 adverse outcomes. The actions of colchicine, one of the oldest anti-inflammatory therapeutics, target multiple mechanisms associated with COVID-19 excessive inflammation. While many COVID-19 trials have sought to manipulate SARS-CoV-2 or dampen the inflammatory response once patients are hospitalised, few examine therapeutics to prevent the need for hospitalisation. Colchicine is easily administered, generally well tolerated and inexpensive, and holds particular promise to reduce the risk of hospitalisation and mortality due to COVID-19 in the outpatient setting. Successful outpatient treatment of COVID-19 could greatly reduce morbidity, mortality and the demand for rare or expensive care resources (front-line healthcare workers, hospital beds, ventilators, biological therapies), to the benefit of both resource-replete and resource-poor regions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|